Page last updated: 2024-12-07

s-sulphocysteine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

S-sulphocysteine: residues in physiologically significant proteins treated with sulfite; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

S-sulfo-L-cysteine : An S-substituted L-cysteine where the S-substituent is specified as a sulfo group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID115015
CHEMBL ID457665
CHEBI ID27891
SCHEMBL ID399716
MeSH IDM0057169

Synonyms (47)

Synonym
C05824
s-sulfo-l-cysteine
1637-71-4
l-cysteine s-sulfate, >=98% (tlc)
cysteine-s-sulfonate
s-sulpho-l-cysteine
l-cysteine s-sulfate
cysteinyl-s-sulfonic acid
cysteinyl-s-sulfonate
s-sulfocysteine
s-sulphocysteine
DB04370
cysteine-s-sulfate
NCGC00163281-02
NCGC00163281-01
3-(sulfosulfanyl)-l-alanine
cysteine-s-sulfonic acid
bdbm50269414
chebi:27891 ,
CHEMBL457665 ,
(2r)-2-amino-3-sulfosulfanylpropanoic acid
(2r)-2-azaniumyl-3-sulfosulfanylpropanoate
l-cysteine hydrogen sulfate
unii-885f2s42ll
l-cysteine, hydrogen sulfate (ester)
885f2s42ll ,
l-cysteine, s-sulfo-
SCHEMBL399716
s-sulfo-l-cysteine sodium salt
NOKPBJYHPHHWAN-REOHCLBHSA-N
s-cysteinesulfonic acid
alaninethiosulfuric acid
l-cysteinesulfonic acid
l-cysteine-s-sulfonate
DTXSID20167649
(2r)-2-amino-3-(sulfosulfanyl)propanoic acid
HY-113084
J-010087
cysteine-s-sulphate
l-cysteine s-sulphate
l-cysteine hydrogen sulfate (ester)
l-cysteine hydrogen sulphate (ester)
(r)-2-amino-3-((sulfooxy)thio)propanoic acid
(r)-2-amino-3-(sulfothio)propanoic acid
Q27095171
CS-0059520
AKOS040758947

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" An affinity difference of three- to eightfold between high-and low-affinity agonist-binding states was estimated from fitting of dose-response data with models containing both types of desensitization."( Desensitization of NMDA receptor channels is modulated by glutamate agonists.
Benveniste, M; Lipinski, D; Nahum-Levy, R; Shavit, S, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
organic thiosulfate
S-substituted L-cysteine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
Cysteine Biosynthesis1329
Methionine metabolism leading to sulfur amino acids and related disorders919
Cysteine and methionine catabolism1436

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
phosphopantetheinyl transferaseBacillus subtilisPotency40.07490.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency10.89510.180013.557439.8107AID1460; AID1468
regulator of G-protein signaling 4Homo sapiens (human)Potency23.77810.531815.435837.6858AID504845
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aspartate-semialdehyde dehydrogenaseHelicobacter pylori 26695IC50 (µMol)0.18000.18000.18000.1800AID402018
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID402018Inhibition of Helicobacter pylori His-tagged ASD assessed as inhibition of phosphorylation of aspartate semialdehyde2005Journal of natural products, May, Volume: 68, Issue:5
Petrosamine B, an inhibitor of the Helicobacter pylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge Oceanapia sp.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (68)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (38.24)18.7374
1990's15 (22.06)18.2507
2000's8 (11.76)29.6817
2010's14 (20.59)24.3611
2020's5 (7.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.31 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.60 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (6.94%)6.00%
Case Studies6 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other61 (84.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]